Development and Clinical validity of a novel blood-based molecular biomarker for sub-clinical acute rejection following kidney transplant
from American Journal of Transplantation
Non‐invasive biomarkers are needed to monitor stable patients following kidney transplantation (KT), as sub‐clinical acute rejection (subAR), currently detectable only with surveillance biopsies can lead to chronic rejection and graft loss. We conducted a multi‐center study to develop a blood‐based molecular biomarker for subAR using peripheral blood paired with surveillance biopsies and strict clinical phenotyping algorithms for discovery and validation.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063